- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03625648
Pentoxifylline in Diabetic Kidney Disease (PTXRx)
CSP #2008 - Pentoxifylline in Diabetic Kidney Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetic kidney disease (DKD) is the most frequent cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the U.S. and in U.S. Veterans. Control of blood pressure and reduction in proteinuria, for instance by blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptors blockers (ARBs), have led to some improvement in outcomes in recent years. However, many patients continue to progress to ESRD, requiring costly dialysis or transplantation and resulting in high mortality. Patients with ESRD on maintenance dialysis also have markedly impaired quality of life. Thus, novel treatments are needed for this disease.
The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease. Therefore, this drug has been in clinical use for over 3 decades and has been found to have an excellent safety profile. Recent experimental and clinical data suggest that PTX, when added to usual care in patients with DKD, leads to a reduction in albuminuria and reduced inflammation, as evidenced by lower levels of inflammatory cytokines, and may decrease progression of renal disease. The available evidence thus suggests the possibility of the use of PTX as a valuable repurposing of an old drug in the treatment of DKD. However, a large scale multicenter randomized clinical trial is needed to determine whether this agent can reduce hard endpoints such as ESRD and death in patients with DKD.
The objective of this study is to test the hypothesis that PTX, when added to usual care, leads to a reduction in the incidence of ESRD and mortality in type-2 diabetic patients with DKD when compared to usual care plus placebo.
The primary endpoint will be time to ESRD or death. ESRD will be defined as need for chronic dialysis or renal transplantation.
Secondary efficacy endpoints will be: (1) quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF), (2) time until doubling of serum creatinine, (3) hospitalization for congestive heart failure (CHF), (4) a three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), (5) peripheral vascular disease (PVD), (6) percentage of participants with 50% reduction in UACR from baseline, (7) Rate of change in eGFR per year during the study period. Safety (serious adverse events and adverse events possibly or probably related to study drug, discontinuation of study drug) will also be analyzed as a secondary safety outcome.
The design will be simple with only 2 face-to-face visits (randomization and end of trial visits). The remaining quarterly contacts can be conducted by telephone collecting minimal targeted information. Laboratory testing specifically for the study will be done only at randomization, at 6 months and the end of the study, if needed. However, coordinators will assure that a serum creatinine will have been measured every 6 months as part of routine clinical care or, in rare instances where one has not been done, obtain this measurement. Other than randomization to PTX or matched placebo, patient care will be handled by usual providers according to recommended standards of care.
There will be a one-year ramp-up phase which will include 6 VA hospitals. The purpose of the ramp-up phase will be to optimize procedures prior to widespread implementation, including assessing the recruitment rate to determine whether the expected rate can be achieved and assessing the efficacy of central distribution of study drug/placebo.
In addition, the investigators will refine methods of recruitment, demonstrate that the proposed follow-up methods are working as intended, and address unforeseen problems. This will be followed by the full study at 40 sites (which includes the 6 ramp-up sites) and will involve 3 years of recruitment and 5 years of follow-up.
Sample size calculation, assuming a 26.6% event rate in the control group and 21.6% event rate in PTX group (corresponding to a 19% relative reduction), two-sided alpha = 0.05, 85% power, a 3-year enrollment period, a minimum 5-year follow-up period, and one proposed interim analysis indicates that 2510 participants will need to be randomized.
If this study is successful and PTX is found to reduce the incidence of ESRD and/or death, this will reduce the personal and financial burden of renal replacement therapy (dialysis/transplantation) for Veterans with diabetic kidney disease
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Douglas E Lammie, MPH RD
- Phone Number: 25746 (708) 202-8387
- Email: douglas.lammie@va.gov
Study Contact Backup
- Name: Cheryl C Odle, MBA
- Phone Number: 23117 (708) 202-8387
- Email: cheryl.odle@va.gov
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Recruiting
- Phoenix VA Health Care System, Phoenix, AZ
-
Contact:
- Penelope Baker, MD
- Email: Penelope.Baker@va.gov
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205-5484
- Recruiting
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
-
Contact:
- Luis Juncos, MD
- Email: Luis.Juncos@va.gov
-
-
California
-
Loma Linda, California, United States, 92357
- Recruiting
- VA Loma Linda Healthcare System, Loma Linda, CA
-
Contact:
- Ronald Fernando, MD
- Email: Ronald.Fernando@va.gov
-
Contact:
- Angela Hawley, MA
- Email: Angela.Hawley@va.gov
-
Long Beach, California, United States, 90822
- Recruiting
- VA Long Beach Healthcare System, Long Beach, CA
-
Contact:
- Joline Joline, MD
- Email: joline.chen@va.gov
-
Contact:
- Aliya Asghar, MPH
- Email: aliya.asghar@va.gov
-
Palo Alto, California, United States, 94304-1207
- Recruiting
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Yiming Lit, MD
- Email: yiming.lit@va.gov
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contact:
- Sophia Ambruso, DO
- Email: sophia.ambruso@va.gov
-
-
Florida
-
Bay Pines, Florida, United States, 33744-0000
- Recruiting
- Bay Pines VA Healthcare System, Pay Pines, FL
-
Contact:
- Hemalatha Gutta, MD
- Email: Hemalatha.gutta@va.gov
-
Gainesville, Florida, United States, 32608-1135
- Recruiting
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
Contact:
- Ashutosh Shukla, MD
- Email: Ashutosh.Shukla@va.gov
-
Tampa, Florida, United States, 33612
- Recruiting
- James A. Haley Veterans' Hospital, Tampa, FL
-
Contact:
- Jorge Lamarche, MD
- Email: jorge.lamarche@va.gov
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Recruiting
- Atlanta VA Medical and Rehab Center, Decatur, GA
-
Contact:
- Lawrence Phillips, MD
- Phone Number: 6839 404-321-6111
- Email: Lawrence.Phillips@va.gov
-
Contact:
- Patricia Maya, RN
- Phone Number: 203120 404321611
- Email: patricia.maya@va.gov
-
-
Illinois
-
Hines, Illinois, United States, 60141-3030
- Recruiting
- Edward Hines Jr. VA Hospital, Hines, IL
-
Contact:
- David J Leehey
- Phone Number: 22781 708-202-8387
- Email: David.Leehey@va.gov
-
Study Chair:
- David J Leehey
-
-
Iowa
-
Iowa City, Iowa, United States, 52246-2292
- Recruiting
- Iowa City VA Health Care System, Iowa City, IA
-
Contact:
- Diana Jalal, MD
- Email: Diana.Jalal@va.gov
-
-
Kentucky
-
Lexington, Kentucky, United States, 40502
- Recruiting
- Lexington VA Medical Center, Lexington, KY
-
Contact:
- Dennis Karounos, MD
- Email: dennis.karounos@va.gov
-
Contact:
- Ruth Oremus, BSN
- Email: ruth.oremus@va.gov
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105-2303
- Recruiting
- VA Ann Arbor Healthcare System, Ann Arbor, MI
-
Contact:
- Timothy Bodnar, MD
- Email: timothy.bodnar@va.gov
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Recruiting
- Minneapolis VA Health Care System, Minneapolis, MN
-
Contact:
- Scott Reule, MD
- Phone Number: 651-402-4881
- Email: scott.reule@va.gov
-
Contact:
- David M Leverty, MPH
- Phone Number: 331027 6127252000
- Email: David.Leverty@va.gov
-
-
Missouri
-
Columbia, Missouri, United States, 65201-5275
- Recruiting
- Harry S. Truman Memorial, Columbia, MO
-
Contact:
- Kunal Chaudhary, MD
- Email: Kunal.Chaudhary@va.gov
-
Kansas City, Missouri, United States, 64128-2226
- Recruiting
- Kansas City VA Medical Center, Kansas City, MO
-
Contact:
- Mariana Garcia-Touza, MD
- Email: mariana.garcia-touza@va.gov
-
Saint Louis, Missouri, United States, 63106-1621
- Recruiting
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO
-
Contact:
- Geetha Maddukuri, MD
- Email: Geetha.Maddukuri@va.gov
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105-1873
- Recruiting
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
-
Contact:
- Robert J Anderson, MD
- Phone Number: 402-995-4312
- Email: robert.anderson4@va.gov
-
Contact:
- Moira Neal, RN
- Phone Number: (402) 9954045
- Email: Moira.neal@va.gov
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108-5153
- Recruiting
- New Mexico VA Health Care System, Albuquerque, NM
-
Contact:
- Brent Wagner, MD
- Email: brent.wagner@va.gov
-
-
North Carolina
-
Durham, North Carolina, United States, 27705-3875
- Recruiting
- Durham VA Medical Center, Durham, NC
-
Contact:
- Patrick Pun, MD
- Email: patrick.pun@va.gov
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Recruiting
- Cincinnati VA Medical Center, Cincinnati, OH
-
Contact:
- Charuhas Thakar, MD
- Email: Charuhas.Thakar@va.gov
-
Contact:
- Samantha Kramer
- Email: samantha.kramer@va.gov
-
Dayton, Ohio, United States, 45428
- Active, not recruiting
- Dayton VA Medical Center, Dayton, OH
-
-
Oregon
-
Portland, Oregon, United States, 97207-2964
- Recruiting
- VA Portland Health Care System, Portland, OR
-
Contact:
- Tonja Dirkx, MD
- Email: Tonja.Dirkx@va.gov
-
Contact:
- Alexandra
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4551
- Active, not recruiting
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
-
-
South Carolina
-
Columbia, South Carolina, United States, 29209-1638
- Recruiting
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC
-
Contact:
- Jennifer Othersen, MD
- Email: Jennifer.Othersen2@va.gov
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Recruiting
- Memphis VA Medical Center, Memphis, TN
-
Contact:
- Barry Wall, MD
- Email: barry.wall@va.gov
-
Contact:
- Lillie Johnson, RN
- Email: lillie.johnson3@va.gov
-
-
Texas
-
Dallas, Texas, United States, 75216-7167
- Recruiting
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Contact:
- Eleanor Lederer, MD
- Email: Eleanor.Lederer@va.gov
-
Houston, Texas, United States, 77030-4211
- Recruiting
- Michael E. DeBakey VA Medical Center, Houston, TX
-
Contact:
- Sankardass Navaneethan, MD
- Email: Sankardass.Navaneethan@va.gov
-
San Antonio, Texas, United States, 78229-4404
- Recruiting
- South Texas Health Care System, San Antonio, TX
-
Contact:
- John Duch, MD
- Email: john.duch@va.gov
-
-
Utah
-
Salt Lake City, Utah, United States, 84148
- Recruiting
- VA Salt Lake City Health Care System, Salt Lake City, UT
-
Contact:
- Srinivasan Beddhu, MD
- Email: Srinivasan.Beddhu@va.gov
-
Contact:
- Kandi Velarde, MPH
- Email: Kandi.Velarde@va.gov
-
-
Virginia
-
Richmond, Virginia, United States, 23249-0001
- Recruiting
- Hunter Holmes McGuire VA Medical Center, Richmond, VA
-
Contact:
- Nilang Patel, MD
- Email: Nilang.Patel3@va.gov
-
Salem, Virginia, United States, 24153-6404
- Recruiting
- Salem VA Medical Center, Salem, VA
-
Contact:
- Devasmita Dev, MD
- Email: devasmita.dev@va.gov
-
-
Washington
-
Seattle, Washington, United States, 98108
- Recruiting
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
Contact:
- Kristina Utzschneider, MD
- Phone Number: 206-277-3568
- Email: Kristina.Utzschneider@va.gov
-
Contact:
- Karen Atkinson, RN
- Phone Number: (206) 7642788
- Email: Karen.Atkinson2@va.gov
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53295-0001
- Recruiting
- Clement J. Zablocki VA Medical Center, Milwaukee, WI
-
Contact:
- Dawn Wolfgram
- Email: dawn.wolfgram@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A. Inclusion Criteria:
- Type 2 diabetes.
Meet one of the following categories at a time that is greater than 90 days prior to randomization
- Group I: eGFR 15 to less than 30 mL/min/1.73 m2, or
- Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR > 30 mg/g or UPCR > 150 mg/g, or
- Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR > 300 mg/g or UPCR > 500 mg/g
Participants need to be in one of the following categories at the time of randomization:
Group I: eGFR 15 to less than 30 mL/min/1.73 m2
, or
- Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR > 30 mg/g, or
- Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR > 300 mg/g
Participants must be a United States Veteran, currently receiving care at a VA hospital with a local study team.
Exclusion Criteria:
- Type 1 diabetes
- History of non-diabetic kidney disease
- Severe comorbid conditions expected to reduce life expectancy to less than 1 year, as determined by LSI
- Active substance abuse, homelessness, or other condition that is likely to result in participant non,ompliance as determined by the LSI
- Previous organ or bone marrow transplant
- Pregnancy, breast feeding or female of child-bearing potential unwilling to use a reliable form of contraception
- A recent (within 3 months) cerebral hemorrhage
- Current use of oral pentoxifylline
- Hypersensitivity to pentoxifylline or any of the components of the formulation
- Current use of systemic ketorolac, oral or IV (contraindicated with pentoxifylline)
- Current use of riociguat (contraindicated with pentoxifylline)
- Current use of dialysis
- Unable to provide informed consent
- or any condition that in the opinion of the LSI would make the potential participant non-compliant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
placebo
|
Experimental: PTX
Active drug
|
The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to ESRD or death
Time Frame: 5 to 9 years
|
ESRD will be defined as need for chronic dialysis or renal transplantation.
|
5 to 9 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (KDQoL-SF)
Time Frame: 5 to 9 years
|
Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)
|
5 to 9 years
|
Time until doubling of serum creatinine
Time Frame: 5 to 9 years
|
Time until doubling of serum creatinine
|
5 to 9 years
|
Incidence of congestive heart failure hospitalization (CHF)
Time Frame: 5 to 9 years
|
The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.
|
5 to 9 years
|
Incidence of a three-point MACE
Time Frame: 5 to 9 years
|
The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.
|
5 to 9 years
|
Incidence of a peripheral vascular disease (PVD)
Time Frame: 5 to 9 years
|
The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.
|
5 to 9 years
|
Percentage of participants with 50% reduction in UACR from baseline
Time Frame: 5 to 9 years
|
Percentage of participants with 50% reduction in UACR from baseline
|
5 to 9 years
|
Rate of change in eGFR per year during the study period
Time Frame: 5 to 9 years
|
Rate of change in eGFR per year during the study period.
|
5 to 9 years
|
Collaborators and Investigators
Investigators
- Study Chair: David J Leehey, Edward Hines Jr. VA Hospital, Hines, IL
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Diabetic Nephropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Pentoxifylline
Other Study ID Numbers
- 2008 (Ministry of Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
Universidad Estatal de MilagroSecretaría de Ciencia, Tecnología e Innovación (Senescyt); PROMETEOUnknownKidney Diseases | Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Chronic Kidney DiseaseEcuador
-
University of California, San DiegoRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States